Development of vaccine against COVID-19

After months of the worldwide spread of the SARS-CoV-2 coronavirus, it is clear that the development and production of a safe and effective vaccine is a promising public policy strategy to combat the pandemic, allowing the complete reopening of the economy and the prevention of new waves. epidemic. The Butantan Institute is a century-old institution dedicated to the development of biological medicines, being responsible for providing 65% of all vaccines and 100% of serums to the public health system in Brazil. Considering its qualification, self-sufficiency and ability to respond with agility to the specific health challenges of the population, the institute has attracted partnerships with the main developers of immunobiologicals in the world for the development and production of vaccines for COVID-19. The agreement signed between Instituto Butantan and Sinovac Biotech Ltd to carry out Phase III of clinical trials and subsequent production of the vaccine developed by the Chinese company is relevant due to the effectiveness demonstrated by the inactivated vaccine in Phases I and II and because it is a traditional and wide use. FAPESP, which has a recognized role in the production of knowledge and new technologies, is fundamental in the search for solutions to urgent issues. The relationship that will be established between Instituto Butantan and Fapesp to support activities that involve the development and regulation of the inactivated vaccine against COVID-19 goes towards the establishment of pandemic control and mitigation policies that impact health and social conditions and country's economic growth. (AU) The relationship that will be established between Instituto Butantan and Fapesp to support activities that involve the development and regulation of the inactivated vaccine against COVID-19 goes towards the establishment of pandemic control and mitigation policies that impact health and social conditions and country's economic growth. (AU) The relationship that will be established between Instituto Butantan and Fapesp to support activities that involve the development and regulation of the inactivated vaccine against COVID-19 goes towards the establishment of pandemic control and mitigation policies that impact health and social conditions and country's economic growth. (AU)